🇺🇸 FDA
Patent

US 12410418

Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome

granted A61PA61P31/20A61P7/04

Quick answer

US patent 12410418 (Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome) held by Precision BioSciences, Inc. expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Precision BioSciences, Inc.
Grant date
Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P31/20, A61P7/04